SERA vs OVID vs NTRA vs ACAD vs EXAS

For growth investors, Ovid Therapeutics Inc.

(OVID) is the stronger pick with 1181% revenue growth year-over-year, versus 5. 2% for Sera Prognostics, Inc. (SERA). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Sera Prognostics, Inc. (SERA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ACADIA Pharmaceuticals Inc.

is actually cheaper at 55. 6x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -83. 9% for Sera Prognostics, Inc. (SERA). Over 10 years, the gap is even starker: NTRA returned +1835% versus SERA's -84. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Sera Prognostics, Inc. 's 1. 54β — meaning SERA is approximately 2825% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Ovid Therapeutics Inc. (OVID) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ovid Therapeutics Inc.

(OVID) is pulling ahead at 1181% versus 5. 2% for Sera Prognostics, Inc. (SERA). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, OVID leads at 69. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -394. 2% for Sera Prognostics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -450. 7% for SERA. At the gross margin level — before operating expenses — OVID leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACADIA Pharmaceuticals Inc.

(ACAD) trades at 55. 6x forward P/E versus 582. 8x for Exact Sciences Corporation — 527. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SERA: 160. 4% to $5. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Sera Prognostics, Inc. (SERA) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, SERA: -84. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SERA is a small-cap quality compounder stock; OVID is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; ACAD is a small-cap deep-value stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.